Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).

In patients who took a second dose for pain recurrence, there was some evidence that a second dose of lasmiditan may offer benefit over placebo for freedom from MBS and pain relief at 2 h; the percentage of patients who were pain free at 2 h was numerically greater with lasmiditan versus placebo as second dose, but the difference did not reach statistical significance.

also in 111,027 other papers